Drugmaker Eli Lilly & Co. agreed to provide 300,000 doses of its experimental Covid-19 antibody drug to the federal government for $375 million, if the medicine is authorized for emergency use in the U.S., the company said Wednesday.
The U.S. Department of Health and Human Services said the federal government will allocate the doses to state and territorial health departments, which will, in turn, determine which hospitals and health facilities get the drug.
Under…
This post first appeared on wsj.com
